Log In
BCIQ
Print this Print this
 

clonoSEQ test

  Manage Alerts
Collapse Summary General Information
Company Adaptive Biotechnologies Corp.
DescriptionImmunosequencing diagnostic to monitor minimal residual disease (MRD) in patients with blood-based cancers
Molecular Target
Mechanism of Action 
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentMarketed
Standard IndicationCancer, Diagnostic
Indication DetailsMonitor MRD in patients with blood-based cancers
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

04/14/2015

Undisclosed

0

0

Get a free BioCentury trial today